title: Development and validation of a stability-indicating high-performance liquid chromatography method for the simultaneous determination of albuterol, budesonide, and ipratropium bromide in compounded nebulizer solutions.
abstract: In recent years, there has been a large increase in the use of pharmaceutical compounding to prepare medications that are not commercially available. The treatment of asthma typically includes the use of albuterol (ALB), ipratropium bromide (IPB), and/or budesonide (BUD) nebulizer solutions. There is currently no commercially available nebulizer solution containing all three of these compounds, and patients must rely on often-unregulated compounding. There is a distinct need for methodologies that can be used to analyze compounded formulations to ensure patient safety. We report an HPLC-UV method to separate and quantitate ALB, IPB, and BUD in nebulizer solutions. The method used a gradient elution to achieve separation via an RP C18 column. The method was validated, showed good selectivity, and was linear over several orders of magnitude. The method was applied to the analysis of nebulizer solutions and determination of their storage stability. Significant ALB-dependent degradation occurred within 5 h in solutions formulated with the free base of ALB, while those containing the sulfate salt of ALB produced no degradation. Alkali solutions can cause base-catalyzed hydrolysis of IPB and degradation of BUD. Compounded formulations containing ALB need to include an acid to control pH and prevent degradation.
authors.affiliation: Temple University, Department of Chemistry, 1901 N. 13th St, Philadelphia, PA 19122, USA.
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Blewett
authors.forename: Deepti
authors.initials: D
authors.lastname: Varma
authors.forename: Tiffany
authors.initials: T
authors.lastname: Gilles
authors.forename: Rashidi
authors.initials: R
authors.lastname: Butcher
authors.forename: Jaini
authors.initials: J
authors.lastname: Jacob
authors.forename: Jean
authors.initials: J
authors.lastname: Amazan
authors.forename: Susan A
authors.initials: SA
authors.lastname: Jansen
mesh_terms: D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage / Q000032:analysis*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000032:analysis; D001249:Asthma / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000032:analysis; D019819:Budesonide / Q000008:administration & dosage / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004339:Drug Compounding; D004355:Drug Stability; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009241:Ipratropium / Q000008:administration & dosage / Q000032:analysis*; D009330:Nebulizers and Vaporizers; D012996:Solutions; D013997:Time Factors
chemical_list: D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D012996:Solutions; D019819:Budesonide; D009241:Ipratropium; D000420:Albuterol